Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Rottenberg

Showing results (661-670 of 684) with videos related to

Pageof 69
Sort By:
Cell Reports|May 10, 2023
MND1 and PSMC3IP control PARP inhibitor sensitivity in mitotic cellsAnabel Zelceski, Paola Francica, Lea Lingg, et al.
Toxicologic Pathology|February 11, 2025
Points to Consider From the ESTP Pathology 2.0 Working Group: Overview on Spatial Omics Technologies Supporting Drug Discovery and DevelopmentKerstin Hahn, Bettina Amberg, Josep M Monné Rodriguez, et al.
Iscience|April 28, 2022
A chemical probe for BAG1 targets androgen receptor-positive prostate cancer through oxidative stress signaling pathwayNane C Kuznik, Valeria Solozobova, Irene I Lee, et al.
Cell Reports|May 20, 2023
Multi-omics analysis reveals distinct non-reversion mechanisms of PARPi resistance in BRCA1- versus BRCA2-deficient mammary tumorsJinhyuk Bhin, Mariana Paes Dias, Ewa Gogola, et al.
Frontiers in Immunology|October 26, 2023
Spore-FP1 tuberculosis mucosal vaccine candidate is highly protective in guinea pigs but fails to improve on BCG-conferred protection in non-human primatesAndrew D White, Andy C Tran, Laura Sibley, et al.
BMC Infectious Diseases|December 1, 2023
Humoral and T cell responses to SARS-CoV-2 reveal insights into immunity during the early pandemic period in PakistanKiran Iqbal Masood, Shama Qaiser, Syed Hani Abidi, et al.
Neurology|April 13, 2012
A randomized, double-blind, placebo-controlled trial of antidepressants in Parkinson diseaseI H Richard, M P McDermott, R Kurlan, et al.
Nature|July 23, 2016
Replication fork stability confers chemoresistance in BRCA-deficient cellsArnab Ray Chaudhuri, Elsa Callen, Xia Ding, et al.
Nature Communications|May 24, 2024
H2AX promotes replication fork degradation and chemosensitivity in BRCA-deficient tumoursDiego Dibitetto, Martin Liptay, Francesca Vivalda, et al.
Frontiers in Medicine|October 16, 2023
A clinical evaluation of an <i>ex vivo</i> organ culture system to predict patient response to cancer therapyShay Golan, Vered Bar, Seth J Salpeter, et al.
Pageof 69

Showing results (661-670 of 684) with videos related to

Sort By:
Pageof 69
Cell Reports|May 10, 2023
MND1 and PSMC3IP control PARP inhibitor sensitivity in mitotic cellsAnabel Zelceski, Paola Francica, Lea Lingg, et al.
Toxicologic Pathology|February 11, 2025
Points to Consider From the ESTP Pathology 2.0 Working Group: Overview on Spatial Omics Technologies Supporting Drug Discovery and DevelopmentKerstin Hahn, Bettina Amberg, Josep M Monné Rodriguez, et al.
Iscience|April 28, 2022
A chemical probe for BAG1 targets androgen receptor-positive prostate cancer through oxidative stress signaling pathwayNane C Kuznik, Valeria Solozobova, Irene I Lee, et al.
Cell Reports|May 20, 2023
Multi-omics analysis reveals distinct non-reversion mechanisms of PARPi resistance in BRCA1- versus BRCA2-deficient mammary tumorsJinhyuk Bhin, Mariana Paes Dias, Ewa Gogola, et al.
Frontiers in Immunology|October 26, 2023
Spore-FP1 tuberculosis mucosal vaccine candidate is highly protective in guinea pigs but fails to improve on BCG-conferred protection in non-human primatesAndrew D White, Andy C Tran, Laura Sibley, et al.
BMC Infectious Diseases|December 1, 2023
Humoral and T cell responses to SARS-CoV-2 reveal insights into immunity during the early pandemic period in PakistanKiran Iqbal Masood, Shama Qaiser, Syed Hani Abidi, et al.
Neurology|April 13, 2012
A randomized, double-blind, placebo-controlled trial of antidepressants in Parkinson diseaseI H Richard, M P McDermott, R Kurlan, et al.
Nature|July 23, 2016
Replication fork stability confers chemoresistance in BRCA-deficient cellsArnab Ray Chaudhuri, Elsa Callen, Xia Ding, et al.
Nature Communications|May 24, 2024
H2AX promotes replication fork degradation and chemosensitivity in BRCA-deficient tumoursDiego Dibitetto, Martin Liptay, Francesca Vivalda, et al.
Frontiers in Medicine|October 16, 2023
A clinical evaluation of an <i>ex vivo</i> organ culture system to predict patient response to cancer therapyShay Golan, Vered Bar, Seth J Salpeter, et al.
Pageof 69